225PD - HER 2 over-expression in patients with esophageal squamous cell carcinoma: Correlation with response to neo-adjuvant chemoradiation and survival

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Gastrointestinal tumours
Topics Anti-Cancer Agents & Biologic Therapy
Oesophageal Cancer
Translational Research
Surgery and/or Radiotherapy of Cancer
Presenter mona Joudi Mashhad
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors K. Anvari1, M. Joudi Mashhad2, M. Silanian Toussi1, S.A. Aledavood3, B. Memar4
  • 1Radiation Oncology, Mashhad University of Medical Sciences-Omid Hospital Cancer Research Center, 9176613775 - Mashhad/IR
  • 2Radiotherapy Oncology Department, Mashhad University of Medical Sciences-Omid Hospital Cancer Research Center, 0000000000 - Mashhad/IR
  • 3Cancer Research Center, Mashhad University of Medical Sciences-Omid Hospital Cancer Research Center, 9176613775 - Mashhad/IR
  • 4Pathology Department, Mashhad University of Medical Sciences-Omid Hospital Cancer Research Center, 9176613775 - Mashhad/IR

Abstract

Background

This study was conducted to investigate the frequency of HER2 over-expressionin patients with Esophageal Squamous Cell Carcinoma (ESCC) and its correlation with pathologic response in cases undergoing neo-adjuvant chemoradiation and survival

Methods

In this cross sectional study, 68 patients with non-metastatic esophageal SCC who had undergone neo-adjuvant chemotherapy containing cisplatin and 5FU in conjunction with radiotherapy (4000 cGy)between years 2007 to 2014 were evaluated. HER2 expression was assessed by Immunohistochemistry (IHC).The results were classified according to the Herceptest criteria (DAKO): negative (0/1+), potential positive (2+) and positive (3+). HER2 score was also calculated for each specimen.

Results

Hercep test was positive in 42.8% of cases, among which 33.8% were 2+ and 8.8% were 3+. Her2 score was above 100 in 32.8%. Complete pathologic response was observed in 32.3%. There was no significant difference in the rate of complete response between patients with positive and negative HER-2 over-expression (P- value =0.71) .There was also no significant correlation between Her2 score among groups with favorable and unfavorable response to chemoradiation (P-value= 0.796 and 0.743 respectively). There was no difference in overall survival in Her2 positive and negative groups (3 years survival was 45 and 54 months respectively, P-value=0.32).Overall survival was significantly reduce in patients with Her2 score above 100 (P-value= 0.045)

Conclusions

Her2 positive in ESCC had no effect in tumors biologic behaviors and its response to chemoradiation. Although no correlation was observed between Her2 expression and survival, Her2 score above 100 was associated with shorter survival.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

This work was extracted from the MSI`s radiation oncology thesis and is supported by Research Deputy of Mashhad University of Medical Sciences

Disclosure

All authors have declared no conflicts of interest.